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Background: Glaucoma is a chronic eye disease associated with irreversible visual loss. In Africa, glaucoma patients
often present late, with very advanced disease. One-off procedures, such as laser or surgery, are recommended in
Africa because of lack of or poor adherence to medical treatment. However, acceptance of surgery is usually
extremely low. To prevent blindness, adherence to treatment needs to improve, using acceptable, replicable and
cost-effective interventions. After reviewing the literature and interviewing patients in Bauchi (Nigeria) motivational
interviewing (MI) was selected as the intervention for this trial, with adaptation for glaucoma (MIG). MI is designed
to strengthen personal motivation for, and commitment to a specific goal by eliciting and exploring a person’s
reasons for change within an atmosphere of acceptance and compassion. The aim of this study is to assess whether
MIG increases the uptake of laser or surgery amongst glaucoma patients where this is the recommended treatment.
The hypothesis is that MIG increases the uptake of treatment. This will be the first trial of MI in Africa.
Methods: This is a hospital based, single centre, randomized controlled trial of MIG plus an information sheet on
glaucoma and its treatment (the latter being “standard care”) compared with standard care alone for glaucoma
patients where the treatment recommended is surgery or laser.
Those eligible for the trial are adults aged 17 years and above who live within 200 km of Bauchi with advanced
glaucoma where the examining ophthalmologist recommends surgery or laser. After obtaining written informed
consent, participants will be randomly allocated to MIG plus standard care, or standard care alone. Motivational
interviewing will be delivered in Hausa or English by one of two MIG trained personnel. One hundred and fifty
participants will be recruited to each arm. The primary outcome is the proportion of participants undergoing laser
or surgery within two months of the date given to re attend for the procedure. MIG quality will be assessed using
the validated MI treatment integrity scale.
Discussion: Motivational interviewing may be an important tool to increase the acceptance of treatment for
glaucoma. The approach is potentially scalable and may be useful for other chronic conditions in Africa.
Trial registration: ISRCTN79330571 (Controlled-Trials.com).
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Glaucoma, a chronic eye disease of unknown cause, is
responsible for irreversible blindness in roughly 8.4 mil-
lion people worldwide [1]. In Nigeria, the prevalence of
blindness in those aged ≥40 years is 4.2% with 16.3% be-
ing due to glaucoma [2]. Glaucoma causes painless, pro-
gressive loss of the peripheral field of vision leading to
total, irreversible blindness [3]. Primary open angle glau-
coma (POAG), which is the most common type in
Africa [4], is asymptomatic in the early stages [5]. In
Africa, patients with glaucoma present very late, usually
with a very advanced stage of the disease [6-11]. In an
earlier unpublished study (Abdull MM, Stage at presen-
tation of primary open angle glaucoma in Northern
Nigeria) in the same clinic in Bauchi, 75% of the eyes of
new glaucoma patients were already blind.
The aim of treatment in glaucoma is to lower the in-
traocular pressure (IOP), which slows or halts progres-
sion [12]. Treatments are daily eye drops, surgery or
laser. Surgery and laser are one-off procedures, and laser
can be repeated. Both have acceptably high rates of suc-
cess. Eye drops (used daily for life) are not recom-
mended in Africa except for educated people who live
near eye units, as adherence in other groups is very low.
Surgery is the recommended treatment for glaucoma in
Africa [13-16]. However, acceptance of surgery can also
be extremely poor. In the earlier unpublished study car-
ried out two years before the trial was planned, fewer
than 5% of people offered surgery (trabeculectomy)
returned for the procedure. Laser treatment was not
available at that time. To prevent glaucoma blindness it
is therefore necessary to improve acceptance and adher-
ence to treatment using approaches that are acceptable,
replicable and cost-effective in the African setting.
Motivational interviewing
A review of the literature on approaches to improve ad-
herence to treatment of any kind, and findings from
qualitative research in Bauchi were used to modify a
form of counseling, called motivational interviewing
(MI) [17]. Motivational interviewing is designed to
strengthen personal motivation for and commitment to
a specific goal by eliciting and exploring the person’s
own reasons for change within an atmosphere of accept-
ance and compassion. It has shown promise in psych-
iatry, substance abuse, and healthy life style changes and
is being increasingly used in other fields of medical and
health care [18-20]. It is an approach that can be taught
at most levels [21,22], although it is complex to learn
and training workshops alone are insufficient. We have
named this modified form of MI as MI modified for
glaucoma (MIG) for the purpose of this study.
A Cochrane review of interventions for improving ad-
herence to eye drops for glaucoma did not find evidenceto support any particular method [23]. None of the stud-
ies included in the review were undertaken in Africa and
there is no review of acceptance of surgery or laser treat-
ment. Other Cochrane reviews show the effectiveness of
MI for other conditions [24,25].
To our knowledge this will be the first trial of this na-
ture to be undertaken in Africa. Similar studies in the
United Kingdom and United States have only assessed
adherence to medical treatment [26,27].
There is a need for a strategy that is both feasible and
effective in increasing awareness about the disease and
its management, and the benefits of treatment, to im-
prove acceptance. MIG is a relatively inexpensive tech-
nology and local people can be trained to deliver it in
the local language. The pilot study described below dem-
onstrated that MIG is acceptable to patients who are not
literate and who have no or little knowledge of glau-
coma. We acknowledge that there are difficulties in
learning and applying this complex approach in the
resource-constrained situation in Nigeria, where expos-
ure to counselling of any type is unusual, and where a
high proportion of the population have not received any
formal education. Bearing this in mind, the two inter-
viewers who will deliver the intervention come from the
same community as study participants and are familiar
with local social constructs, customs, beliefs and com-
munication patterns, and are also bilingual in English
and the predominant local language, Hausa.
The quality of counselling is important in all studies of
this type. The Working Alliance Inventory questionnaire
(WAI) [28] has been developed to assess the perceptions
of both the counsellor and the participant. In this trial,
WAI questionnaires will be completed immediately after
the MIG session and analyzed as in other studies
[29,30]. Recorded interviews will also be assessed for fi-
delity by independent experts, using the motivational
interviewing treatment integrity (MITI) scale, a validated
tool used for the fidelity testing of MI [31].
Pilot study October 2012 to March 2103
The purpose of the pilot study was to assess the accept-
ability and quality of MIG in adults with advanced glau-
coma, to refine the study protocol and finalize data
forms, to provide data for the sample size calculation, to
refine recruitment and randomization processes and to
estimate recruitment rates. The primary outcome was
acceptance of laser or surgery on the date given, which
was around one month after the date of diagnosis, re-
cruitment and randomization.
Findings of the pilot study
All those eligible to be included in the pilot study agreed
to take part, approximately 20 eligible patients were re-
cruited each month, and the method of randomization
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numbers allocated to MIG or no MIG. All who were of-
fered a MIG interview accepted, and interviews took 20
to 30 minutes per session. None of those offered a sec-
ond session returned and some participants preferred to
have a relative or companion with them. None found
the process distressing and reviewing the transcripts
showed the quality of the MIG sessions to be satisfac-
tory, but with room for improvement. Data on the pri-
mary outcome were available on 45 participants
(Table 1). Nine of the nineteen (47%) participants who
had undergone MIG underwent treatment compared with
nine of the twenty six participants (35%) who had not
undergone MIG. MIG therefore increased treatment rates
by 12%. Overall acceptance was 40%, and 75% of these
participants underwent laser treatment over surgery. No
participants attended for surgery after the date given.
We concluded that MIG is acceptable and the time
interval for the primary outcome can be reduced from
acceptance within four months of the date given for sur-
gery or laser treatment, to acceptance within two
months, as all those accepting treatment did so on the
date given and none returned at a later date. Laser treat-
ment is deemed to be more acceptable than surgery.
Methods/Design
The primary hypothesis is that MI, locally adapted for
glaucoma and its treatment (MIG), increases the uptake
of treatment amongst individuals with advanced glau-
coma in Bauchi State, Nigeria.
A randomized controlled trial with 1:1 allocation to
intervention or no intervention will be used to test this
hypothesis.
Study setting
This is a single centre trial, taking place at Abubakar
Tafawa Balewa University Teaching Hospital (ABUTH),
Bauchi, Bauchi State, Nigeria. Dr M Abdull is the senior
ophthalmologist. The eye department is new and has re-
cently been re-equipped and additional staff appointed.
Participant eligibility
Inclusion criteria
Inclusion criteria for the trial are as follows: must be
aged 17 years or above, have a confirmed diagnosis ofTable 1 Pilot study
Had surgery
Yes No
MIG Yes 9 10 19 47.4%
No 9 17 26 34.6%
18 27 45
MIG, motivational interviewing modified for glaucoma.POAG, have surgery or laser agreed to be the best op-
tion for further treatment, are able to understand Hausa
or English, and must live within 200 km of the clinic.
Exclusion criteria
Exclusion criteria for the study are as follows: patient
does not consent, there are other ocular morbidities,
any diagnosed systemic diseases that contraindicate sur-
gery or laser, communication problems (such as pro-
found deafness), previous eye surgery (except cataract
surgery), or have been referred to Abubakar Tafawa
Balewa University Teaching Hospital (ATBUTH) specif-
ically for glaucoma surgery.
Identification of potential participants and recruitment
Potential participants will be those with POAG where the
examining ophthalmologist recommends surgical treat-
ment (trabeculectomy with or without anti-scarring
agents) or laser (diode laser trans-scleral cycloablation
treatment of the ciliary body which is being increasingly
used for advanced glaucoma) [32,33]. Patients with POAG
will be identified by screening everyone aged 17 years and
above who attends the outpatient department, regardless
of their presenting complaint(s) (Additional file 1). Stand-
ard clinical procedures will be used to detect people who
the ophthalmic nurse or optometrists suspect as having
glaucoma, who will then be examined by an ophthalmolo-
gist to confirm the diagnosis. Criteria for referral to the
ophthalmologist are one or more of the following:
A cup disc ratio of 0.7 or more in one or both eyes.
Optic discs will be assessed in all patients by direct oph-
thalmoscopy through undilated pupils in a dark room. If
the disc is not visible, the Van Herrick’s test will be car-
ried out to exclude narrow angles. The pupils will be
dilated and optic discs examined at the slit lamp using
a +60D lens; Cup disc ratio difference of 0.2 or more be-
tween the two eyes. Examination as before. The cup disc
ratio of the two eyes will be compared to detect differ-
ences of 0.2 or more; Positive family history of glaucoma
regardless of the eye findings. In the Rotterdam study
there was a 9.2 relative risk for individuals with a family
history of glaucoma [34]. In the Tasmania study the odds
ratio of having a positive family history of POAG was
4.1 [35]. A person has a 20% risk if a parent has the dis-
ease, increasing to 50% for a sibling; IOP greater than
26 mmHg in the absence of a view of the discs, even
after dilated examination, measured by Goldman appli-
cation tonometry using standard techniques; Relative ap-
parent pupillary defect (RAPD) assessed in a darkened
room using the swinging flash light test [36]; and high
myopia or history of distance spectacle use because of
the association with glaucoma [37].
Everyone suspected of having glaucoma will be re-
ferred to the ophthalmologist (usually Dr Abdull, but
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those who are eligible) for a detailed routine ophthalmic
examination. The ophthalmologist will confirm the diag-
nosis of POAG and determine the treatment of choice
based the clinical findings (severity) and socio-economic
factors likely to influence adherence to medical treat-
ment (such as education and distance from the hospital).
Long-term eye drops will be recommended for those
who live near the hospital, are educated and can afford
topical medication. These individuals will not be eligible
for recruitment. Surgery or laser treatment will be rec-
ommended for those with an advanced stage of the dis-
ease where this offers the best hope for preventing
blindness. These individuals will be potential partici-
pants. The ophthalmologist will then explain the disease,
the treatment options, and the purpose of treatment, as
is standard of care. Participants will choose whether to
have laser treatment or surgery. The ophthalmologist
will then prescribe eye drops and explain how they are
to be used whilst waiting for surgery or laser treatment.
Everyone offered surgery or laser treatment will be given
a date within one month to re-attend for the procedure.
Their name and hospital registration number will be
written in the surgical register. They will then be
escorted to the project manager for recruitment. Partici-
pants wishing to change their date of treatment will be
offered a new date, and the surgical register, data record
form and spreadsheet will be updated.
The eligibility of each potential participant will be
checked by the project manager. All those eligible will
be recruited after obtaining written informed consent. If
the patient does not consent, reasons will be sought and
recorded. After obtaining consent a unique identifier
number will be issued. All those recruited will be given a
red ID card which contains their name, hospital number
and study ID. They will be required to present this card
at the registration desk at every visit.
Randomization
The randomization list was generated in Excel, using the
rand between function by Jennifer Evans, away from the
project site. Block randomization with a variable block
size was used to ensure that the groups will be balanced
over time, as the uptake of laser treatment or surgery
may fluctuate over time.
The option of MIG or no MIG was printed on headed
paper which was signed and stamped. Each was placed
in sequentially-numbered opaque envelopes according to
the randomization schedule. Each envelope was sealed
and stamped. The same was done for randomization to
interviewer A or B. These procedures were undertaken
in London by persons not involved in the trial.
For each participant, the interviewer in Bauchi will
take the next envelope in the sequence and open it tosee whether the patient is allocated to MIG or not. They
will write the sequence number on the participant’s form
and their unique ID number on the outside of the enve-
lope. After returning the letter to the envelope, the enve-
lope will be kept in a sealed, locked container. The same
process will be followed for allocation to interviewer A
or B.
All participants, whether randomized to MIG or not,
will be given an educational graphic leaflet called ‘Silent
Thief ’ (Additional file 2). All participants will, therefore,
receive some additional information about glaucoma and
its management.
MIG Intervention
Two trained personnel will deliver MIG sessions (Figure 1).
The interview will be conducted in a quiet room within
the clinic, in the participant’s preferred language (Hausa
or English). Interviewers and participants will be asked
to switch off their mobile phones. The participant may
be accompanied by someone of their choice.
The interviewers will introduce themselves and explain
that the session will be confidential. The interviewer will
then try to engage the participant by presenting an
agenda for discussion, giving the participant the option
to choose where to start. The topics covered will be:
awareness of glaucoma and the consequences of no
treatment; acceptance of treatment options, especially
surgery; adherence to topical medication when pre-
scribed; and need for follow up to monitor the pressure
inside the eye.
Open-ended questions will be used, with active listen-
ing and reflections. The interviewer will seek to under-
stand the participant’s perspective in an empathic
fashion. Participant autonomy will be honored as infor-
mation on glaucoma and its treatment will only be given
if requested, or after gaining permission if the partici-
pant seems ready for this. The interviewer will listen for
change talk, such as participants showing desire for sur-
gery with terms like ‘I wish to’; or an ability to undergo
surgery, with ‘I can’; or a reason for change, such as ‘I
need vision to save my job’; or commitment, with terms
like ‘I intend to’; or even a statement showing that the
participant is already taking steps to come for surgery, ‘I
have discussed the need for financial support with my
family’. The interviewer responds appropriately with re-
flections, affirmations, and requests for further elabor-
ation or further evocation. At the end of the session, a
summary of the interview will be presented to the par-
ticipant by the interviewer.
The MIG sessions will seek to follow the spirit of MI,
and will be recorded for later fidelity testing. Each inter-
view session will last 30 to 60 minutes. All interview re-
cords will be kept in a locked cabinet in the office. After
the interview, the WAI Short Questionnaire will be
Figure 1 Randomization Flow chart. IOP, intraocular pressure; MIG, motivational interviewing modified for glaucoma.
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sess the interviewer and patient’s thoughts about the
interview.
Under some circumstances a second MIG session
might be required if the participant could not stay for
the session on the day of recruitment, if the interview
was not completed as the participant had to leave, or if
there were frequent interruptions from the companion
or others. If, in the opinion of the interviewer, the
session could not be conducted as planned, the reasons
will be recorded and the participant offered a second
session.
Assessing the quality of the MIG intervention
This will be undertaken in three ways. Firstly, the WAI
Short Questionnaire, which is completed by the inter-
viewer and participant immediately after the session,
will be used to investigate the relationship between the
perceived quality of the interview and trial outcomes
(Additional files 3 and 4). Participants who cannot seewell, or who cannot read the questionnaire themselves will
have the questions read out to them by the other inter-
viewer (to reduce bias). Secondly, a random sample of in-
terviews in English, and translated interview transcripts in
Hausa will be sent for independent fidelity testing using
the MITI scale, a validated tool used for fidelity testing of
MI. Thirdly, taped interviews in Hausa and English will be
listened to by Dr Abdull and the interviewers on a regular
basis throughout the trial as part of supervision sessions,
to discuss how well the sessions are going, to identify is-
sues which arise and learning needs, and how interviewing
could be improved.Outcomes
Primary outcome
The primary outcome will be the proportion of partici-
pants undergoing laser treatment or surgery within two
months of the date given to attend the hospital for the
procedure (Table 2. Participant timeline).
Table 2 Participants time line
Participant timeline:
T0 T1 T2 T3
Date for surgery/laser + 2 months T0 + 6 months T0 + 12 months
Diagnosis of glaucoma X
Standard explanation of disease/treatment X





Attended for surgery/laser Yes/No
Secondary outcome assessment:
Visual acuity and IOP X X
Other measures:
Adherence to topical medication X X
Reasons for not undergoing procedure X
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At 6 and 12 months after randomization the following
will be assessed and recorded: mean IOP (can be mea-
sured by Tonopen in their home, if needed); propor-
tion with loss of three of more lines of visual acuity,
or loss of form vision (cannot read any letters on the
chart) measured using a LogMar chart. This can be
measured in their home, if needed; and mean number
of follow-up visits to monitor IOP and other clinical
parameters.
Other data
At 6 months from the date given for laser treatment or
surgery, a subset of participants in each arm of the trial
who do not undergo laser treatment or surgery will be
contacted and asked to return to the clinic. Those who
attend will be re-offered treatment; those who do not at-
tend will be visited in their homes. The following data
will be collected from all: scores using the Morisky ques-
tionnaire to assess adherence to topical medication, and
reasons why participants did not undergo surgery or
laser in both arms of the trial.
Sample size calculation
The sample size is based on the primary outcome and
calculated using the SAMPSI command in Stata 12.1
statistical software (StataCorp Texas, USA). Based on
the pilot study, we anticipate that 35% of participants in
the standard care group will undergo surgery or laser
within two months of the date given for the procedure.
A sample size of 150 in each arm will be required to de-
tect an acceptance rate of 52.5% (50% relative and 17.5%
absolute increase in acceptance) in people in the interventionarm (power 0.8, alpha 0.05). This is based on a calcula-
tion of 137 in each arm rounded up to 150 in each arm
to allow for loss to follow-up. We believe this absolute
increase of 17.5% (corresponding to a relative increase
of 50% assuming a 35% acceptance in the control group)
would be an important effect to detect. We have also
calculated the power of a study of this size to detect dif-
ferences between the treatment groups with respect to
the secondary outcomes. IOP at entry to the study will
average approximately 35 mmHg (SD +/- 14 mmHg)
(values resulting from the pilot study). Our outcome is
based on the final IOP at 12 months. This is likely to be
in the order of 25 mmHg in the standard care group.
The study will have good power (0.84) to detect differ-
ences of 5mmHG or more between the two groups at
one year.
We have less information on the probability of los-
ing three or more lines of visual acuity over the year.
Figure 2 shows the proportion of participants losing
three or more lines of visual acuity in the standard
care group, with power curves for risk ratios of 0.5
and 0.8. It is more likely that we will be able to detect
risk ratios in the order of 0.5. The power of the study
to detect significant differences using a relative risk of
0.5 is shown in Table 3.Blinding
Only participants allocated to MIG and the interviewers
will know who has been allocated to MIG. The project
manager and study ophthalmologist, who will be respon-
sible for obtaining and checking data on the primary
outcome, will be blinded to the intervention.
Figure 2 Proportion of participants losing three or more lines
of visual acuity in the standard care group. RR, Relative risk.
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Primary outcome
All data on socioeconomic variables, clinical findings
and the date given for surgery will be entered into a cus-
tomized database on the day of recruitment. Software
will be used to generate a spreadsheet which will be
constantly updated. The spreadsheet will have the pa-
tient’s unique ID, name, sex, hospital number, detailed
address, contact phone number, the date given for sur-
gery (or the revised date, if relevant), the date the pa-
tient came for surgery and the ‘tracing date’ (date two
months after the date given for surgery). The spread-
sheet will not contain the randomization sequence
number to maintain blinding. The software will be pro-
grammed to indicate the date two months after the date
booked for laser treatment or surgery (or the revised
date). This is the ‘tracing date’ when participants will be
traced (see below). Every surgery day the spreadsheet
will be reviewed to identify participants who should at-
tend for surgery or laser treatment that day. The surgi-
cal register will be checked to see who did and who didTable 3 Power of the study to detect significant
differences using a relative risk of 0.5
% in standard care group losing 3 or more












RR, Relative risk.not attend on the appointed operation day. The data re-
cording form will be completed. The data will be en-
tered into the database so that the spreadsheet can be
updated.
Secondary outcomes
These outcomes will be assessed at 6 and 12 months
after randomization. Participants may also attend at
other time points for clinical reasons. At the 6 month
(+/- one month) and 12 month visits (+/- one month), a
full clinical examination will be performed on those who
return. Data on IOP and visual acuity will be recorded.
Participants who do not attend the 6 and/or 12 month
visits will be traced, initially by telephone, requesting
them to visit. If they still do not attend the clinic, they
will be visited in their home, where their visual acuity
will be measured using a LogMAR chart, and IOPs mea-
sured using a Tonopen.
Other measures
These will be assessed at 6 and 12 months after
randomization. Adherence to topical medication in those
not undergoing surgery or laser treatment will be assessed
using the Morisky score [14] (Additional file 5). This can
be administered over the phone, if necessary. Prior to
assessing reasons for not undergoing surgery or laser
treatment, the following will be assessed after taking ver-
bal consent: a) whether they did in fact attend for surgery
at ABUTH, but slipped through the net; b) they under-
went surgery or laser treatment in another hospital, or
were given more eye drops elsewhere; and c) they have
not had any treatment for their glaucoma apart from the
eye drops given at the time of recruitment.
Those who have not had any further treatment will be
interviewed to find out why they did not attend. This
can be administered over the phone. A subset of those
not attending will be selected randomly, and visited in
their homes for in-depth interviews where they will be
asked why they did not return to the hospital. Responses
will be probed to better understand the barriers that led
to non-acceptance of laser or surgery. See Additional file
6 for the interview guide and probe questions.
Data collection
The following data will be collected using pre-tested
data forms (Additional file 5).
Before and after recruitment at T0
Data will be collected for name, age, gender, clinical
findings and date given to attend for surgery or laser
treatment. For those who refuse, reasons for not agreeing
to participate will be sought. For those who agree, contact
details will be recorded: detailed address; telephone num-
bers of individual/family/neighbor; sociodemographic data
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tered into a customized, password protected database on
the day of recruitment. The form will be kept in a lockable
cupboard only accessible to the project manager in an of-
fice dedicated to the trial, which is locked when not in use.
For those allocated to MIG the interview will be con-
ducted at T0. If a second MI session is indicated, the
reason for this will be recorded. After every interview,
WAI questionnaires will be completed independently by
the participant and the interviewer. These forms will be
kept in a lockable cupboard in a separate office dedi-
cated to the MIG interviews. This office will be locked
at all times when not in use for MIG sessions. The pro-
ject manager and ophthalmologist will not have access
to these forms at any time. Data from these forms will
be entered into a separate password protected database.
At time of ascertainment of primary outcome T1
Information on whether the participant underwent laser
or surgery, which procedure was performed, and the
date of the procedure will be recorded.
At time of ascertainment of secondary outcomes
T2 and T3
The date attended and the IOP and visual acuity in the
study eye will be recorded. The Morisky Adherence
questionnaire will be administered. At T2 only, the rea-
sons for not undergoing surgery or laser will be sought
using closed-ended questions. Consent will be obtained
to record all in-depth interviews. (See Additional file 6
for interview guide for in-depth interviews.)
Data management
Data entry
Databases have been created in Epidata and Access, with
range and consistency checks. Data will be double en-
tered by the project manager, who has been trained in
data entry. Data will be entered as soon as possible after
recruitment, so that the ‘surgery date’ and ‘tracing date’
outputs can be generated (as above). Random checks of
the quality of data entry will be undertaken by Dr Abdull
on a regular basis. Frequency distributions will be ex-
plored and data of outliers checked for accuracy.
Data analyses
The randomization code will only be broken once ana-
lysis of the primary outcome is completed. We will pre-
pare a flow chart describing participant flow through the
trial. This diagram will provide data on the following:
the number of eligible people approached to take part in
the trial, the number of people who agreed to take part,
reasons for non-participation, the number of people ran-
domly allocated to MIG and no MIG, the number of
people who received the intervention as randomized, thenumber of people with data on the primary outcome by
the intervention group, and the number of people
followed up at 6 and 12 months by the intervention
group.
We will compare people who agreed to take part in
the trial with people who did not agree to take part in
terms of age, sex, education and stage of glaucoma to as-
sess the generalizability of the findings. All participants
will be analyzed in the group to which they were ran-
domized (by intention to treat).
We will compare the characteristics of the people in
the two intervention groups with respect to age, sex,
education, distance from hospital and stage of glaucoma
at presentation to assess the balance between interven-
tion groups.
We will describe the quality of the MIG in two ways.
Firstly, by the WAI questionnaire scores for participants’
and interviewers’ perceptions of the MIG sessions. We
will analyze this as a continuous variable but it is likely
that the data will be skewed and we will therefore
present medians, ranges and interquartile ranges, by
interviewer. We will also compare this to other pub-
lished data on WAI scores. Secondly, by fidelity testing
using the MITI scale, which generates a series of scores
that can be categorized as good or poor. We will present
results by interviewer as done in published studies using
the MITI.
Primary outcome
Our primary outcome is dichotomous (did or did not at-
tend surgery or laser treatment within two months of
their scheduled date). Our effect measure will be the risk
ratio, that is, we will calculate the proportion of people
with this outcome in the intervention group compared
to the standard care group. We will report this with 95%
confidence intervals. In a trial of 300 people we antici-
pate that the groups will be fairly well balanced. How-
ever, we will also calculate a risk ratio adjusted for
factors that may affect uptake of surgery (stage of glau-
coma, age, sex, education, and distance from hospital).
Secondary outcomes
We will analyze the dichotomous secondary outcomes in
the same way. For the continuous secondary outcomes
we will calculate the mean difference with 95% confi-
dence intervals, if the data are reasonably normally dis-
tributed. Otherwise we will compare the two groups
using the median value and assess the role of chance
using non-parametric tests.
Subgroup analysis
We plan two subgroup analyses of the primary out-
come. We will calculate the primary outcome risk ratio
and do a test for interaction in the following subgroups:
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‘Poor’ sessions according to the MITI scale (see above).
We will tabulate reasons for not attending for surgery
or laser treatment or follow-up by intervention group
and the Morisky adherence scores by intervention
group.
Consolidated Standard of Reporting Trials (CONSORT)
guidelines will be used when reporting results.
Qualitative data
Interview recordings in Hausa will be transcribed and
translated into English, if required. Transcripts will
be coded using N vivo (QSR International, Victoria,
Australia) and analyzed to identify reasons why individ-
uals did not undergo the treatment recommended and
to explore barriers.
Data monitoring
A Data Management Committee will be established,
chaired by an independent clinical trialist. Membership
to be confirmed. Stopping rules will not be required, as
the intervention is acceptable and is unlikely to cause
harm. The pilot study has also demonstrated that MIG
is of a modest benefit. Interim analyses will not be
undertaken. Meetings will be held regularly throughout
the trial (every 6 months) to assess progress and advise
if problems arise, and to assist in interpreting the results.
Additional meetings will be called if required.
Ethics and dissemination
Ethical approval has been obtained from the Interven-
tions Ethics Committee of the London School of Hy-
giene & Tropical Medicine, and from the Institutional
Review Board of ATBUTH, Bauchi.
Protocol amendments
Important protocol amendments will be communicated
to the Data Management Committee, the Interventions
Ethics Committee of the London School of Hygiene and
Tropical Medicine, the trial register, and will be reported
in publications and reports.
Consent
Written informed consent will be obtained by the pro-
ject manager. The information sheet and consent form
will be available in Hausa and English. For those who
cannot see well enough to read, or who cannot read, the
information sheet will be read out and they will sign or
provide a thumb print, which will be witnessed by the
project manager. Additional consent will be obtained
from those selected for in depth interviews. Specific con-
sent will be obtained to record the interview, and for
any anonymous quotes to be used.Confidentiality
The names, ID and hospital number of those taking part
in the trial will only be known to project staff. Study ID
numbers will not be entered into the surgical register.
As the surgery date and the date to start tracing individ-
uals for primary outcome data requires names and hos-
pital numbers, these will be need to be entered into the
database.
Analysis of all the outcome data will be undertaken
after removing all identifiers from the database and any
quotes taken from the in depth interviews will use an-
onymous codes.
Access to data
The following individuals will have access to trial data:
Clare Gilbert, Dr Abdull and Jennifer Evans.
Post-trial care
Standard clinical care will be provided to all study par-
ticipants. No adverse events are anticipated.
Discussion
The trial is designed to assess the effectiveness of MIG
in Nigeria in encouraging patients to accept surgery or
laser treatment. The MI has been adapted because it is
being undertaken in a language other than English and
in a different culture where counselling is not the norm;
it may be difficult to achieve the proficiency possible in
a western audience. In the interview, questions, reflec-
tions and providing information are done in strict adher-
ence to the spirit of MI. Interviews are conducted in the
local language (Hausa), however participants who under-
stand English may wish to be interviewed in English. At
present, the fidelity assessment of motivational inter-
views using the MITI scale is conducted in English, but
after discussion with the assessor it has been agreed that
transcribed and translated interviews will also be used
for assessment. However, transcripts lead to loss of
vital information such as tone of voice, pauses and em-
pathetic sounds. Assessing only interviews conducted in
English may lead to bias, as participants who speak Eng-
lish are likely to be better educated and more aware of
glaucoma and its treatment.
The initial plan was to offer participants the option to
come back for a second MIG session if they so desired,
however, in the pilot study no-one returned for a second
interview.
During the pilot study the duration of the interviews
increased over time as the interviewers gained both ex-
perience and confidence. In the main trial participants
will be told that the interview will last up to 60 minutes.
The longer time will allow participants to ask more
questions and so gain greater understanding of the deci-
sion they are being asked to make.
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low a guide by Foster et al. [38] and the values for cup:
disc ratios and IOP come from the normative dataset of
the Nigeria blindness and low vision survey (unpub-
lished data (Kyari F, Normative data for glaucoma in
Nigeria. Results from the National Blindness and Low
Vision Survey Project)). A limitation of our study is that
visual field testing to aid detection of glaucoma is not
feasible in a busy eye clinic. The criteria being used may
miss some early glaucoma cases, but these individuals
would not be eligible for the trial.
The sample size was calculated assuming that 35% of
people in the control group will accept surgery. This es-
timate was obtained from a small pilot study and there-
fore may be unreliable. If the true acceptance in the
control group is 30% then the study will be underpow-
ered to detect a risk ratio of 1.5 (power = 0.69), however
it will have good power to detect marginally larger risk
ratios of 1.6 or more (corresponding to an absolute in-
crease of 18% of more) (power = 0.84). If the true accept-
ance in the control group is higher, for example, at 40%
then the study will have good power to detect a risk ra-
tio of 1.5 (power = 0.90) (corresponding to an absolute
increase of 20% or more). The planned sample size is
feasible given the time and resources available for the
study and the estimate of acceptance from the pilot
study is the best that is available. With the present sam-
ple size, subgroup analyses may not be adequately pow-
ered to make conclusive inferences.
MI has the potential to be taken to scale in Nigeria
and other limited-resource settings, as pre-existing skills
in counselling are not required. Indeed, it has been sug-
gested that counselling-naïve individuals are better at MI
than those with previous experience, as the main qual-
ities required are empathy, good listening skills and pa-
tience. MI also has the potential to be used for other eye
conditions where uptake is known to be poor (such as
cataract surgery, or lid surgery for trachoma cases) or
for other non-ocular conditions.Trial status
Recruitment started on 2 September 2013. By the end of
January 2014, 70 participants had been recruited, and
only one of those eligible has refused.Additional files
Additional file 1: Randomization flowchart: Flow chart of activities.
Additional file 2: Glaucoma the silent thief: Educational material.
Additional file 3: Working alliance inventory for interviewer:
Questionnaire.
Additional file 4: Working alliance inventory for patient:
Questionnaire.Additional file 5: Main data record form: Main form for data
capture.
Additional file 6: Interview guide: Interview guide for those who
fail to attend for surgery/laser.
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